• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility.通过不对称膜的渗透流:一种控制递送不同溶解度药物的方法。
AAPS PharmSciTech. 2006 Jul 7;7(3):56. doi: 10.1208/pt070356.
2
In Situ Phase-Transited Asymmetric Membrane Capsules: A Means for Achieving Delayed and Osmotic Release for pH Solubility-Dependant Drugs.原位相转变不对称膜胶囊:一种实现pH溶解度依赖性药物延迟和渗透释放的方法。
PDA J Pharm Sci Technol. 2011 Jan-Feb;65(1):32-41.
3
Phase Transited Asymmetric Membrane Capsule: A Means for Achieving Delayed and Controlled Osmotic Flow.相变不对称膜胶囊:一种实现延迟和可控渗透流的手段。
Curr Drug Deliv. 2010 Jul;7(3):230-7. doi: 10.2174/156720110791560964.
4
Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.氟比洛芬通过原位形成的不对称膜胶囊的渗透调节流动。
Curr Drug Deliv. 2008 Apr;5(2):127-32. doi: 10.2174/156720108783954824.
5
Phase transited and vapor-induced dual capsular system (DCS) for achieving delayed and osmotic release of cefadroxil.相转变和蒸气诱导双重囊系统(DCS)用于实现头孢羟氨苄的迟效和渗透释放。
Pharm Dev Technol. 2011 Oct;16(5):457-65. doi: 10.3109/10837450.2010.485321. Epub 2010 May 20.
6
In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug.用于难溶性药物渗透释放的原位形成不对称膜胶囊。
PDA J Pharm Sci Technol. 2007 Jan-Feb;61(1):24-36.
7
Osmotically regulated floating asymmetric membrane capsule for controlled site-specific delivery of ranitidine hydrochloride: optimization by central composite design.渗透压调节型漂浮不对称膜胶囊用于盐酸雷尼替丁的控制型定位释放:通过中心复合设计进行优化。
AAPS PharmSciTech. 2012 Dec;13(4):1492-501. doi: 10.1208/s12249-012-9870-8. Epub 2012 Oct 27.
8
Asymmetric membrane in membrane capsules: a means for achieving delayed and osmotic flow of cefadroxil.膜胶囊中的不对称膜:实现头孢羟氨苄延迟和渗透流动的一种手段。
Eur J Pharm Biopharm. 2008 Jun;69(2):658-66. doi: 10.1016/j.ejpb.2007.12.011. Epub 2007 Dec 23.
9
Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug.湿法诱导相转变药物递送系统:一种实现难溶性药物渗透、控释和A级体内体外相关性的手段。
Drug Dev Ind Pharm. 2008 Jul;34(7):735-43. doi: 10.1080/03639040801911032.
10
Asymmetric membrane capsules of phenylephrine hydrochloride: an osmotically controlled drug delivery system.盐酸苯福林不对称膜囊:一种渗透压控制的药物传递系统。
Curr Drug Deliv. 2011 Sep;8(5):474-82. doi: 10.2174/156720111796642345.

引用本文的文献

1
Phase transited asymmetric membrane floating nanoparticles: a means for better management of poorly water-soluble drugs.相转变不对称膜浮载纳米粒:改善难溶性药物制剂的手段
Daru. 2021 Dec;29(2):241-253. doi: 10.1007/s40199-020-00382-5. Epub 2021 Aug 20.
2
Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring.下消化道中的药物处置:靶向与监测
Pharmaceutics. 2021 Jan 26;13(2):161. doi: 10.3390/pharmaceutics13020161.
3
Dexamethasone implant in silicone oil: in vitro behavior.硅油中的地塞米松植入物:体外行为
Int J Retina Vitreous. 2018 Jun 20;4:24. doi: 10.1186/s40942-018-0127-x. eCollection 2018.
4
Cellulose Acetate 398-10 Asymmetric Membrane Capsules for Osmotically Regulated Delivery of Acyclovir.用于阿昔洛韦渗透调控递送的醋酸纤维素398 - 10不对称膜胶囊
J Pharm (Cairo). 2016;2016:8471520. doi: 10.1155/2016/8471520. Epub 2016 Feb 11.
5
Colon-targeted oral drug delivery systems: design trends and approaches.结肠靶向口服给药系统:设计趋势与方法
AAPS PharmSciTech. 2015 Aug;16(4):731-41. doi: 10.1208/s12249-015-0350-9. Epub 2015 Jun 13.
6
Asymmetric membrane osmotic capsules for terbutaline sulphate.用于硫酸特布他林的非对称膜渗透胶囊。
Indian J Pharm Sci. 2012 Jan;74(1):69-72. doi: 10.4103/0250-474X.102546.
7
Osmotically regulated floating asymmetric membrane capsule for controlled site-specific delivery of ranitidine hydrochloride: optimization by central composite design.渗透压调节型漂浮不对称膜胶囊用于盐酸雷尼替丁的控制型定位释放:通过中心复合设计进行优化。
AAPS PharmSciTech. 2012 Dec;13(4):1492-501. doi: 10.1208/s12249-012-9870-8. Epub 2012 Oct 27.
8
Osmotically regulated two-compartment asymmetric membrane capsules for simultaneous controlled release of anti-hypertensive drugs.用于同时控释抗高血压药物的渗透调节双室不对称膜胶囊。
Sci Pharm. 2012 Jan-Mar;80(1):229-50. doi: 10.3797/scipharm.1106-01. Epub 2011 Dec 23.
9
Solubility-modulated asymmetric membrane tablets of triprolidine hydrochloride: statistical optimization and evaluation.三羟甲基丙烷盐酸盐溶解度调节不对称膜片:统计优化与评价。
AAPS PharmSciTech. 2012 Mar;13(1):174-83. doi: 10.1208/s12249-011-9738-3. Epub 2011 Dec 20.
10
Colon targeted drug delivery systems: a review on primary and novel approaches.结肠靶向给药系统:关于主要方法和新方法的综述
Oman Med J. 2010 Apr;25(2):79-87. doi: 10.5001/omj.2010.24.

本文引用的文献

1
MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.缓释药物的作用机制。分散于固体基质中的固体药物释放速率的理论分析。
J Pharm Sci. 1963 Dec;52:1145-9. doi: 10.1002/jps.2600521210.
2
Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.关于具有原位形成给药孔的不对称膜包衣胶囊药物释放机制的研究。
J Control Release. 2003 Apr 14;89(1):57-69. doi: 10.1016/s0168-3659(03)00091-9.
3
The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation.术前局部应用氟比洛芬或双氯芬酸对瞳孔散大的影响。
Eye (Lond). 2000 Aug;14 ( Pt 4):642-5. doi: 10.1038/eye.2000.157.
4
Asymmetric membrane capsules for osmotic drug delivery II. In vitro and in vivo drug release performance.用于渗透给药的不对称膜胶囊II。体外和体内药物释放性能。
J Control Release. 1999 Jan 4;57(1):65-73. doi: 10.1016/s0168-3659(98)00101-1.
5
Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process.用于渗透控释给药的不对称膜胶囊。I. 制备工艺的开发
J Control Release. 1999 Jan 4;57(1):55-64. doi: 10.1016/s0168-3659(98)00100-x.
6
Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air.氯化钾从压缩的亲水性聚合物基质中释放的机制:截留空气的影响。
J Pharm Sci. 1983 Oct;72(10):1189-91. doi: 10.1002/jps.2600721021.
7
Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix.
J Pharm Sci. 1966 Nov;55(11):1230-4. doi: 10.1002/jps.2600551113.
8
A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s.
Pharmacotherapy. 1986 Jan-Feb;6(1):10-25. doi: 10.1002/j.1875-9114.1986.tb03445.x.
9
The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.
Pharm Res. 1991 Jan;8(1):88-92. doi: 10.1023/a:1015890525495.
10
Elementary osmotic pump.基本渗透泵
J Pharm Sci. 1975 Dec;64(12):1987-91. doi: 10.1002/jps.2600641218.

通过不对称膜的渗透流:一种控制递送不同溶解度药物的方法。

Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility.

作者信息

Philip Anil K, Pathak Kamla

机构信息

Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, 286001, Uttar Pradesh, India.

出版信息

AAPS PharmSciTech. 2006 Jul 7;7(3):56. doi: 10.1208/pt070356.

DOI:10.1208/pt070356
PMID:17025237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2750498/
Abstract

A nondisintegrating, controlled release, asymmetric membrane capsular system of flurbiprofen was developed and evaluated for controlled release of the drug to overcome some of its side effects. Asymmetric membrane capsules were prepared using fabricated glass mold pins by phase inversion process. The effect of different formulation variables was studied based on 2(3) factorial design; namely, level of osmogen, membrane thickness, and level of pore former. Effects of polymer diffusibility and varying osmotic pressure on drug release were also studied. Membrane characterization by scanning electron microscopy showed an outer dense region with less pores and an inner porous region for the prepared asymmetric membrane. Differential scanning calorimetry studies showed no incompatibility between the drug and the excipients used in the study. In vitro release studies for all the prepared formulations were done (n = 6). Statistical test (Dunnett multiple comparison test) was applied for in vitro drug release at P > .05. The best formulation closely corresponded to the extra design checkpoint formulation by a similarity (f2) value of 92.94. The drug release was independent of pH but dependent on the osmotic pressure of the dissolution medium. The release kinetics followed the Higuchi model and the mechanism of release was Fickian diffusion.

摘要

开发并评估了一种用于氟比洛芬控释的非崩解型、控释、不对称膜胶囊系统,以克服其一些副作用。采用预制玻璃模具销通过相转化法制备不对称膜胶囊。基于2(3)析因设计研究了不同处方变量的影响,即渗透剂水平、膜厚度和成孔剂水平。还研究了聚合物扩散性和不同渗透压对药物释放的影响。扫描电子显微镜对膜的表征显示,制备的不对称膜有一个孔较少的外部致密区域和一个内部多孔区域。差示扫描量热法研究表明,药物与研究中使用的辅料之间不存在不相容性。对所有制备的制剂进行了体外释放研究(n = 6)。对体外药物释放应用统计学检验(Dunnett多重比较检验),P > 0.05。最佳制剂与额外设计检查点制剂的相似性(f2)值为92.94,非常接近。药物释放与pH无关,但取决于溶出介质的渗透压。释放动力学遵循Higuchi模型,释放机制为菲克扩散。